Ionis Pharmaceuticals stock price target maintained at $100 by H.C. Wainwright on HBV approval
H.C. Wainwright maintained a $100 price target for Ionis Pharmaceuticals (IONS) after GSK's Hibsago received FDA approval, which will generate royalties for Ionis. The stock is near its 52-week low, down 44% year-to-date. Analysts estimate Japan alone could generate $21M-$26M in annual royalties at peak. Other analysts have also recently upgraded or maintained positive ratings on IONS.
How this was made
The 30-second read
Why it matters
The approval is a primary regulatory event that can materially affect Ionis’s valuation and stock price.
Market read
Regulatory approval creates immediate upside for Ionis and may influence related biotech stocks.
What to watch
Potential competition from other HBV therapies and the need for sustained commercial uptake in Japan and the U.S.
Background
Ionis Pharmaceuticals (NASDAQ:IONS) received FDA approval for GSK’s Hibsago, a hepatitis B drug, triggering royalty revenue expectations.
Ticker impact
FDA approval of GSK’s Hibsago (bepirovirsen) for chronic hepatitis B will generate royalties for Ionis, prompting H.C. Wainwright to maintain a $100 price target.
likely upward pressure as investors price in royalty revenue and the $100 target.
Regulatory clearance is a material catalyst for a biotech with a royalty stream; analysts have already raised targets, indicating strong market reaction.
Market effects
Boosts the biotech royalty‑revenue sub‑sector and may lift peers with similar licensing models.
Positive for US biotech stocks; limited direct impact on other regions.
Adds to overall optimism in the hepatitis‑B treatment space worldwide.
Counterpoint
Royalty forecasts may be optimistic; actual sales could lag, limiting upside.
Key entities
- companyIonis Pharmaceuticals
Biotech firm receiving royalty revenue from Hibsago.
- companyGSK
Developer and commercializer of Hibsago.
- analystH.C. Wainwright
Maintains $100 price target on Ionis.
